10th International Meeting of Pediatric Endocrinology

at the Marriott Wardman Park


Satellite Symposia

We are excited to present an update of the Satellite Symposia that will be offered at the 10th International Meeting of Pediatric Endocrinology. These sessions, generously hosted and supported by industry sponsors, will cover a wide range of interesting and timely topics designed to complement the meeting's scientific program, presented by foremost international experts.




Satellite Title: Pediatric Growth Hormone Deficiency: Management of the Transition from Pediatric to Adult Care
Room: Washington 4-6
Company/Organization Name: Ferring Pharmaceuticals
Description: The treatment of pediatric growth hormone deficiency (GHD) is essential for assuring optimization of growth during childhood and achievement, if possible, of the patient's genetic target height. Many of these patients, but not necessarily all, are candidates for transition to GH treatment as adults. The goals of this symposium are to discuss:

1) The rationale for continued treatment of pediatric GHD patients as adults
2) Determination of which pediatric patients should continue treatment as adults
3) How transition from pediatric to adult endocrine care can be best accomplished

Please click here for the final agenda.

Satellite Title: Personalized Approach in Diagnosis and Management of Short Stature
Room: Thurgood Marshall
Company/Organization Name: Merck KGaA, Darmstadt, Germany
Description: In this audience interactive scientific session, it will be debated whether genetic analysis is essential for optimal management of short stature and whether individualization of therapy is essential for optimal management of growth hormone deficiency. Leading experts will present arguments for and against these two statements during separate debates before opening the question to the audience, who shall be able to register their opinions through real-time voting.


Satellite Title: Understanding Short Stature Beyond the GH-IGF Axis
Room: Washington 1-3
Company/Organization Name: Sandoz
Description: Understanding short stature beyond the GH-IGF axis is an educational symposium, sponsored by Sandoz, being held during the 10th International Meeting of Paediatric Endocrinology, Washington, USA.  Short stature and growth are familiar topics to pediatric endocrinologists; however there has recently been increased focus and attention on aspects of short stature beyond the GH-IGF axis. During this symposium, global experts will provide the latest insights into three key areas: genotype/phenotype characterization of newly discovered growth disorders; epigenetic and environmental impact on growth and development; and novel treatment approaches of short stature.



Satellite Title: Improving Care for Patients with Turner Syndrome
Room: Marriott Ballroom
Company/Organization Name: American Academy of CME, Inc. and Scherer Clinical Communications (Under an educational grant from Novo Nordisk Inc.)
Description: Improving Care for Patients with Turner Syndrome will review the new international Turner syndrome clinical practice guideline to be available in mid-2017. The presenters will summarize key recommendations contained in the 2017 guideline and point out the ways in which recommendations have changed since 2007. This symposium will focus on the areas in which improvements in patient management are most urgently needed: expediting the diagnosis of Turner syndrome, ensuring that newly diagnosed patients receive necessary screenings and that established patients receive necessary monitoring at recommended intervals, and making sure that patients receive hormone replacement therapy (GH and estrogen) using the right agent, beginning at the right time, at the most appropriate, individualized doses, and for the optimal duration.

For more information or to register for this symposium, please visit us at:




Satellite Title: Perspectives on Growth and Growth Disorders
Room: Maryland
Company/Organization Name: Pfizer, Inc.
Description: The focus of this symposium is to provide novel perspectives on growth and growth disorders with emphasis on long term metabolic effects in SGA children, management of PWS children with growth hormone and impact of clinical and non clinical factors on transition phase.

Satellite Title: New Perspectives on Rare Forms of Genetic Obesity
Room: Thurgood Marshall
Company/Organization Name: Rhythm Pharmaceuticals
Description: Topics

  • Neural and Physiological Mechanisms Involved in Human Energy Balance by Sadaf Farooqi, PhD, FRCP, FMedSci
  • Genes to Pathways and Pathways to Treatment by Lee Kaplan, MD, PhD
  • Finding Treatable Genetic Obesity: Strategies for Success by Jennifer Miller, MD

Satellite Title:The Evolving Portrait of X-linked Hypophosphatemia
Room: Washington 1-3
Company/Organization Name: Ultragenyx Pharmaceutical

  • Understanding the diagnosis of XLH – Dr. Carpenter
  • Mechanism of FGF23 on phosphate homeostasis - Dr. Perwad
  • Treatment outcomes in children with XLH – Dr.-Linglart
  • Long-term effects of XLH on the adult patient - Dr. Imel





Satellite Title: A Rare Cause of Short Stature You Don't Want to Miss
Room: Delaware
Company/Organization Name: Sanofi Genzyme
Description: Sanofi Genzyme is committed to empowering the lives of patients with rare diseases. Individuals with rare diseases frequently experience a prolonged diagnostic journey which may result in delayed or ineffective disease intervention. Join us for an interactive discussion that will explore a rare but manageable genetic disease characterized by short stature and additional findings that you may recognize in your patient population.




Satellite Title: Central Precocious Puberty: Case Presentations and Discussion of Nuances in Diagnosis, Treatment, and Follow-ups
Room: Marriott Ballroom
Company/Organization Name: Abbvie
Description: Central Precocious Puberty:  A Clinical Discussion and Patient Case Presentations with Dr. Karen Klein and Dr. Peter Lee.

  • CPP is defined as early onset of secondary sexual characteristics (generally earlier than 8 years of age in girls and 9 years of age in boys) associated with pubertal pituitary gonadotropin activation. It may show a significantly advanced bone age that can result in diminished adult height.
  • The signs and symptoms of CPP can be challenging to recognize and may be diagnosed too late. Timely recognition followed by appropriate treatment is crucial to patients achieving optimal outcomes.

Satellite Title: Evolving Trends in Puberty
Room: Washington 1-3
Company/Organization Name:  Endo Pharmaceuticals
Description: Three experts will focus on evolving trends in puberty and the modern day factors influencing pubertal timing and tempo.

Puberty Through the Ages: A Historical Perspective
Lawrence A. Silverman, MD

The Genetics of Pubertal Timing
Yee-Ming Chan, MD, PhD

Influence of Environmental Exposures on Pubertal Timing & Tempo
Mary M. Lee, MD

Satellite Title: Updated Guidelines for the Use of Growth Hormone Therapy in Children and Adolescents: Exploring the Impact on Clinical Practice
Room: Thurgood Marshall
Company/Organization Name: Versartis, Inc.
Description: The program will examine the updated guidelines recently proposed by the Drug and Therapeutics and Ethics Committees of the Pediatric Endocrine Society (Grimberg A, et al. Horm Res Paediatr. 2016; 86:361-397). The clinical management of pediatric patients with growth hormone deficiency (GHD) will focus on diagnosing GHD, dosing, and safety. Challenges related to insurance coverage, outcome measures, and the clinical impact of guidelines will be discussed. Newer therapeutic formulations on the horizon will also be explored.

Presenting Speakers: Pinchas Cohen, MD and Bradley S. Miller, MD, PhD
Moderated by: Paul Saenger, MD, MACE

To register for this event (encouraged but not required), please select this link: